21.33 -0.93 (-4.18%)
Pre-Market: 7:40AM EDT
|Bid||21.31 x 1000|
|Ask||21.40 x 800|
|Day's Range||21.91 - 22.28|
|52 Week Range||10.85 - 25.96|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.53|
Express Scripts Holding Co (ESRX.O), one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly (LLY.N) and Amgen Inc (AMGN.O), but is excluding a rival medication made by Teva Pharmaceutical Industries Ltd (TEVA.TA) after price negotiations with all three manufacturers. The decision represents a setback for Teva, which is in the midst of a corporate restructuring and had hoped to capture a sizable stake of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use to the patients it says are most likely to benefit from the new Amgen and Lilly migraine drugs.
Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.
In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.
A U.S. appeals court on Friday upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd on its blockbuster multiple sclerosis drug Copaxone. The ruling was a victory for a group of generic drug companies, including Mylan NV and Novartis AG unit Sandoz, that challenged the validity of Teva's patents in order to sell generic versions. Teva did not immediately respond to requests for comment.
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.
Leerink raised its recommendation on Teva Pharmaceutical Industries from “underperform” to “market perform.” The firm also raised its target price from $16 to $24 on October 1. The stock registered a rise of ~3.6% during premarket trading on the day. Teva has strong fundamentals that have been improving recently due in part to the more stable generics pricing environment in the United States.
Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.
Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the European launch of Life Effects, a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) Congress in Berlin. With content developed in collaboration with patients, Life Effects consists of articles, videos and podcasts that offer information, insight and inspiration to people suffering from one or more chronic condition, including MS, particularly focusing on the impact a condition has on a patient’s day-to-day life. By working with a core group of patients on an ongoing basis, who make direct contributions which are reviewed by experts, Life Effects offers a first-hand, credible perspective on what it’s like to live with a chronic condition.
Warren Buffett is one of the most successful investors (if not the most) of all time, and chief stock-picker for Berkshire Hathaway (BRK.B). Since assembling the group of companies that would eventually become Berkshire back in 1964, the so-called Oracle of Omaha's baby has trounced the broad market's return. That has led the market to hunt down so-called "Warren Buffett stocks" in hopes of benefitting from his wisdom and discipline. But Buffett, at 88 years of age, already has had to step away from complete control of Berkshire Hathaway, unable to keep up the pace of study needed to keep his fund's holdings optimized. Other acolytes have emerged, and out of necessity have started making stock picks for Berkshire without necessarily requiring Buffett's blessing. Todd Combs and Ted Weschler are at least running a big part of the show. Their selections aren't always divulged as non-Buffett picks. From a shareholder's perspective, Berkshire and its collective chiefs are one and the same, and reported as such. It's sometimes quite clear, though, that Warren Buffett had little-to-nothing to do with a particular holding. Here are five Berkshire Hathaway holdings that might not necessarily be "Warren Buffett stocks." That's because they're out of character with the decades' worth of insight and tips he's been willing to dish out. More importantly: They might give us clues as to the direction of Berkshire's picks once Buffett is completely out of the picture. SEE ALSO: How Well Do You Really Know Warren Buffett?
Celltrion, Inc. (068270.KS) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted unanimously 16-0 to recommend approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan®1 (rituximab) for the treatment of adult patients in three proposed indications.
The extension study initially examined the safety of COPAXONE® 20 mg/mL daily and then also the 40 mg/mL three times weekly formulation when it became available approximately 20 years later. Patients who participated in the original 36-month, randomized placebo-controlled U.S. trial were eligible to proceed to the open-label extension, in which patients receiving COPAXONE® continued their treatment, while those who received placebo were switched to COPAXONE®. Results show that for study patients who continued to take COPAXONE®, long-term treatment has an acceptable safety and tolerability profile with low rates of serious adverse events (SAEs) and immediate post-injection reactions (IPIRs).
Today, Morgan Stanley downgraded Mylan (MYL) from “overweight” to “equal weight.” The firm also cut its target price for MYL stock from $46 to $36. Also, Mylan has seen lower-than-expected sales from its biosimilar and complex products portfolio, which it’s increasingly focusing on in the wake of increasing generics competition and pricing pressures. Today, MYL stock fell ~2.7% during premarket trading.
Even with positive near-term catalysts, Mylan NV (NASDAQ: MYL ) suffers from “uncertain prospects” that warrant a neutral stance, according to Morgan Stanley. The Rating Analyst David Risinger downgraded ...
Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.
Teva Pharmaceutical Industries Ltd. today announced that new data on COPAXONE® , a product for relapsing forms of multiple sclerosis , will be presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin, October 10-12, 2018.
GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will release its third quarter 2018 financial results on Thursday, November 1, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its third quarter 2018 results and overall business environment.
GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.
Medincell SA said late Wednesday that it expected to raise €30 million ($34.6 million) after the success of its initial public offering, noting that the sum could increase to €32.5 million if the overallotment option is fully exercised. The IPO will bring Medincell’s market capitalization to about €144.1 million, according to the company. French venture investor CM-CIC Innovation took a minority stake in Medincell in October 2017.
On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ (ACOR) Ampyra (dalfampridine), which is used for improvement in walking for adults who have multiple sclerosis. Mylan’s dalfampridine extended-release tablets are available in 10 mg tablets, similar to Acorda’s Ampyra. On September 21, MYL stock rose ~2.2% before closing up ~0.67% over the previous day’s closing price.
Teva Pharmaceutical Industries Ltd. (TEVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.
Leerink analyst Ami Fadia upgraded TEVA Pharmaceutical from Underperform to Market Perform and raised the price target from $16 to $24. Goldman Sachs analyst Jami Rubin reiterated a Buy rating on Teva with a $30 price target. Leerink's Fadia considers a more stable pricing environment and improved indicators of FDA approval to be the pharma stock's main growth drivers.